This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia
by Kinjel Shah
After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $148.23, marking a +1.36% move from the previous day.
AstraZeneca Resumes Japan Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in Japan resume. The U.S. study remains on hold.
Bayer (BAYRY) Provides Bleak Guidance for 2021 Crop Division
by Zacks Equity Research
Bayer (BAYRY) confirmed its adjusted guidance for 2020 and expects 2021 sales approximately in line with 2020 levels, despite significant headwinds from the COVID-19 pandemic.
Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs
by Kinjel Shah
New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
by Zacks Equity Research
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
J&J Simponi Aria Gets FDA Nod for Pediatric Use in Arthritis
by Zacks Equity Research
FDA approves J&J's (JNJ) Simponi Aria for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) and juvenile psoriatic arthritis (jPsA) in patients two years of age and older.
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $147.11, marking a +1% move from the previous day.
Endo Up on COVID-19 Vaccine Manufacturing Deal with Novavax
by Zacks Equity Research
Endo (ENDP) and Novavax enter a manufacturing agreement for the latter's COVID-19 vaccine candidate, NVX-CoV2373.
The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK
Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates
by Kinjel Shah
J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.
Company News for Sep 24, 2020
by Zacks Equity Research
Companies in the news are: JKS, JNJ, SPI, MNOV
Stock Market News for Sep 24, 2020
by Zacks Equity Research
Lawmakers' struggle to introduce an additional stimulus package and fresh spike in coronavirus infection dragged major indexes down on Wednesday.
4 Coronavirus Vaccine Makers Now in Phase III as J&J Begins Study
by Kinjel Shah
COVID-19 vaccine candidates of four companies - J&J, Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna - are now in late-stage development.
The Zacks Analyst Blog Highlights: MA, DIS, BAC, JNJ and CSCO
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MA, DIS, BAC, JNJ and CSCO
Tesla's Battery Day Fizzles, J&J's Phase 3 Sizzles
by Mark Vickery
J&J shares are up more than 2% this morning on the announcement it has begun its phase 3 trials for its Covid-19 vaccine candidate.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $144.21, marking a -0.61% move from the previous day.
AstraZeneca's Lynparza Gets CHMP Nod for Two New Indications
by Zacks Equity Research
AstraZeneca's (AZN) PARP inhibitor, Lynparza, nears approval as a treatment for prostate cancer, and first-line maintenance treatment for ovarian cancer in combination with Avastin in Europe.
4 Biotechs That Have More Than Doubled Thanks to Coronavirus
by Kinjel Shah
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.